服用直接口服抗凝药的患者结肠息肉切除术后并发症风险较低
基于美国大型保险数据库的回顾性分析,纳入2011至2015年接受结肠镜息肉切除或内镜下黏膜切除的成人,比较服用直接口服抗凝药(DOAC)、华法林、氯吡格雷与未用抗血栓药者的30天并发症。调整桥接抗凝、内镜下黏膜切除、查尔森共病指数和CHADS2评分后,DOAC组胃肠道出血、脑血管意外、心肌梗死和住院的比值比均未达统计学显著升高。
要点
- 服用DOAC者息肉切除术后胃肠道出血率为0.63%,未用抗血栓药对照为0.2%。
- 调整桥接抗凝、内镜下黏膜切除、查尔森共病指数和CHADS2评分后,DOAC组胃肠道出血比值比0.90(95%CI 0.44-1.85),未达统计学显著。
- 氯吡格雷、华法林、桥接抗凝、较高CHADS2评分、查尔森共病指数和内镜下黏膜切除与并发症风险升高相关。
核心结论
- 在大型国家数据库的回顾性分析中,服用DOAC的患者息肉切除术后胃肠道出血、心肌梗死、脑血管意外或住院的调整后比值比未达统计学显著升高。
- 桥接抗凝、较高CHADS2评分、查尔森共病指数和内镜下黏膜切除是胃肠道出血、心肌梗死、脑血管意外和住院的风险因素。
- 需要研究以确定高危患者的最佳围手术期剂量。
研究设计与样本
- 使用Optum去标识化Clinformatics Data Mart数据库(2003-2016年)进行回顾性分析。
- 纳入2011年1月1日至2015年12月31日接受结肠镜息肉切除或内镜下黏膜切除的成人。
- 抗血栓药组共11,504例(DOAC 1,590例、华法林3,471例、氯吡格雷6,443例),未用目标抗血栓药对照599,983例。
主要发现
- 息肉切除术后并发症不常见,但接受任何抗血栓药者发生率显著高于对照(P < .001)。
- DOAC组胃肠道出血率0.63%(95%CI 0.3%-1.2%),对照组0.2%(95%CI 0.2%-0.3%)。
- DOAC组脑血管意外率0.06%(95%CI 0.01%-0.35%),对照组0.04%(95%CI 0.04%-0.05%)。
- 调整桥接抗凝、内镜下黏膜切除、查尔森共病指数和CHADS2评分后,DOAC组胃肠道出血比值比0.90(95%CI 0.44-1.85)、脑血管意外比值比0.45(95%CI 0.06-3.28)、心肌梗死比值比1.07(95%CI 0.14-7.72)、住院比值比0.86(95%CI 0.64-1.16),均未达统计学显著。
- 氯吡格雷、华法林、桥接抗凝、较高CHADS2、查尔森共病指数和内镜下黏膜切除与并发症风险升高相关。
关键数值与推荐
- DOAC组胃肠道出血率0.63%(95%CI 0.3%-1.2%),对照组0.2%(95%CI 0.2%-0.3%)。
- DOAC组脑血管意外率0.06%(95%CI 0.01%-0.35%),对照组0.04%(95%CI 0.04%-0.05%)。
- 调整后DOAC组胃肠道出血比值比0.90(95%CI 0.44-1.85)。
- 调整后DOAC组脑血管意外比值比0.45(95%CI 0.06-3.28)。
- 调整后DOAC组心肌梗死比值比1.07(95%CI 0.14-7.72)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Use of direct-acting oral anticoagulants (DOACs) is increasing, but little is known about the associated risks in patients undergoing colonoscopy with polypectomy. We aimed to determine the risk of post-polypectomy complications in patients prescribed DOACs. METHODS: We performed a retrospective analysis using Optum's de-identified Clinformatics Data Mart Database (2003-2016) (a de-identified administrative database from a large national insurance provider) to identify adults who underwent colonoscopy with polypectomy or endoscopic mucosal resection (EMR) from January 1, 2011, through December 31, 2015. We collected data from 11,504 patients prescribed antithrombotic agents (1590 DOAC, 3471 warfarin, and 6443 clopidogrel) and 599,983 patients not prescribed antithrombotics of interest (controls). We compared 30-day post-polypectomy complications, including gastrointestinal bleeding (GIB), cerebrovascular accident (CVA), myocardial infarction (MI), and hospital admissions, of patients prescribed DOACs, warfarin, or clopidogrel vs controls. RESULTS: Post-polypectomy complications were uncommon but occurred in a significantly higher proportion of patients receiving any antithrombotic vs controls (P < .001). The percentage of patients in the DOAC group with GIB was 0.63% (95% CI, 0.3%-1.2%) vs 0.2% (95% CI, 0.2%-0.3%) in controls. The percentage of patients with CVA in the DOAC group was 0.06% (95% CI, 0.01%-0.35%) vs 0.04% (95% CI, 0.04%-0.05%) in controls. After we adjusted for bridge anticoagulation, EMR, Charlson comorbidity index (CCI), and CHADS2 (congestive heart failure, hypertension, age over 75, diabetes, stroke [double weight]) score, patients prescribed DOACs no longer had a statistically significant increase in the odds of GIB (odds ratio [OR], 0.90; 95% CI, 0.44-1.85), CVA (OR, 0.45; 95% CI, 0.06-3.28), MI (OR, 1.07; 95% CI, 0.14-7.72), or hospital admission (OR, 0.86; 95% CI, 0.64-1.16). Clopidogrel, warfarin, bridge anticoagulation, higher CHADS2, CCI, and EMR were associated with increased odds of complications. CONCLUSION: In our retrospective analysis of a large national dataset, we found that patients prescribed DOACs did not have significantly increased adjusted odds of post-polypectomy GIB, MI, CVA, or hospital admission. Bridge anticoagulation, higher CHADS2 score, CCI, and EMR were risk factors for GIB, MI, CVA, and hospital admissions. Studies are needed to determine the optimal peri-procedural dose for high-risk patients.
引用
- Yu JX, Oliver M, Lin J, et al. Patients Prescribed Direct-Acting Oral Anticoagulants Have Low Risk of Postpolypectomy Complications. Clin Gastroenterol Hepatol. 2018. PMID: 30503964. doi:10.1016/j.cgh.2018.11.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。